Top

Published in:

01-11-2016 | Mini Review

Estrogens and selective estrogen receptor modulators in acromegaly

Authors: Felipe H. Duarte, Raquel S. Jallad, Marcello D. Bronstein

Published in: Endocrine | Issue 2/2016

Abstract

Despite recent advances in acromegaly treatment by surgery, drugs, and radiotherapy, hormonal control is still not achieved by some patients. The impairment of IGF-1 generation by estrogens in growth hormone deficient patients is well known. Patients on oral estrogens need higher growth hormone doses in order to achieve normal IGF-1 values. In the past, estrogens were one of the first drugs used to treat acromegaly. Nevertheless, due to the high doses used and the obvious side effects in male patients, this strategy was sidelined with the development of more specific drugs, as somatostatin receptor ligands and dopamine agonists. In the last 15 years, the antagonist of growth hormone receptor became available, making possible IGF-1 control of the majority of patients on this particular drug. However, due to its high cost, pegvisomant is still not available in many centers around the world. In this setting, the effect of estrogens and also of selective estrogen receptor modulators on IGF-1 control was reviewed, and proved to be an ancillary tool in the management of acromegaly. This review describes data concerning their efficacy and place in the treatment algorithm of acromegaly.

T.A. Howlett, D. Willis, G. Walker, J.A. Wass, P.J. Trainer, U.K.A.R.S. Group, Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin. Endocrinol. (Oxf) 79(5), 689–699 (2013). doi:10.1111/cen.12207

S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509–1517 (2009). doi:jc.2008-2421 [pii] 10.1210/jc.2008-2421PubMedCrossRef

P. Burman, A.G. Johansson, A. Siegbahn, B. Vessby, F.A. Karlsson, Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J. Clin. Endocrinol. Metab. 82(2), 550–555 (1997). doi:10.1210/jcem.82.2.3776 PubMed

J.O. Jorgensen, J.J. Christensen, M. Krag, S. Fisker, P. Ovesen, J.S. Christiansen, Serum insulin-like growth factor I levels in growth hormone-deficient adults: influence of sex steroids. Horm. Res 62(Suppl 1), 73–76 (2004). doi:10.1159/000080762 PubMed

J.M. Janssen, R. Bland, M. Hewison, M.W. Coughtrie, S. Sharp, J. Arts, H.A. Pols, J.P. van Leeuwen, Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J. Cell Biochem. 75(3), 528–537 (1999)PubMedCrossRef

A.J. Brooks, J.W. Wooh, K.A. Tunny, M.J. Waters, Growth hormone receptor; mechanism of action. Int. J. Biochem. Cell Biol. 40(10), 1984–1989 (2008). doi:10.1016/j.biocel.2007.07.008 PubMedCrossRef

D.J. Waxman, C. O’Connor, Growth hormone regulation of sex-dependent liver gene expression. Mol. Endocrinol. 20(11), 2613–2629 (2006). doi:10.1210/me.2006-0007 PubMedCrossRef

O.M. Vidal, R. Merino, E. Rico-Bautista, L. Fernandez-Perez, D.J. Chia, J. Woelfle, M. Ono, B. Lenhard, G. Norstedt, P. Rotwein, A. Flores-Morales, In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol. Endocrinol. 21(1), 293–311 (2007). doi:10.1210/me.2006-0096 PubMedCrossRef

B. Dawson-Hughes, D. Stern, J. Goldman, S. Reichlin, Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J. Clin. Endocrinol. Metab. 63(2), 424–432 (1986). doi:10.1210/jcem-63-2-424 PubMedCrossRef

10.

A.G. Nugent, K.C. Leung, D. Sullivan, A.T. Reutens, K.K. Ho, Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin. Endocrinol. (Oxf) 59(6), 690–698 (2003). doi:10.1046/j.1365-2265.2003.01907.x CrossRef

11.

J. Gibney, G. Johannsson, K.C. Leung, K.K. Ho, Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. J. Clin. Endocrinol. Metab. 90(7), 3897–3903 (2005). doi:10.1210/jc.2005-0173 PubMedCrossRef

12.

J.J. Kelly, I.A. Rajkovic, A.J. O’Sullivan, C. Sernia, K.K. Ho, Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin. Endocrinol. (Oxf) 39(5), 561–567 (1993)CrossRef

13.

D.M. Cook, W.H. Ludlam, M.B. Cook, Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J. Clin. Endocrinol. Metab. 84(11), 3956–3960 (1999). doi:10.1210/jcem.84.11.6113 PubMed

14.

A.J. Weissberger, K.K. Ho, L. Lazarus, Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J. Clin. Endocrinol. Metab. 72(2), 374–381 (1991). doi:10.1210/jcem-72-2-374 PubMedCrossRef

15.

T. Wolthers, D.M. Hoffman, A.G. Nugent, M.W. Duncan, M. Umpleby, K.K. Ho, Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am. J. Physiol. Endocrinol. Metab. 281(6), E1191–E1196 (2001)PubMed

16.

K.E. Friend, M.L. Hartman, S.S. Pezzoli, J.L. Clasey, M.O. Thorner, Both oral and transdermal estrogen increase growth hormone release in postmenopausal women—a clinical research center study. J. Clin. Endocrinol. Metab. 81(6), 2250–2256 (1996). doi:10.1210/jcem.81.6.8964860 PubMed

17.

K.K. Ho, A.J. Weissberger, Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J. Bone. Miner. Res. 7(7), 821–827 (1992). doi:10.1002/jbmr.5650070711 PubMedCrossRef

18.

J. Slowinska-Srzednicka, S. Zgliczynski, W. Jeske, U. Stopinska-Gluszak, M. Srzednicki, A. Brzezinska, W. Zgliczynski, Z. Sadowski, Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J. Endocrinol. Invest. 15(7), 533–538 (1992)PubMedCrossRef

19.

R.B. Colletti, J.D. Roberts, J.T. Devlin, K.C. Copeland, Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer. Res. 49(7), 1882–1884 (1989)PubMed

20.

E.A. Lien, D.C. Johannessen, A. Aakvaag, P.E. Lonning, Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J. Steroid. Biochem. Mol. Biol. 41(3-8), 541–543 (1992)PubMedCrossRef

21.

M. Pollak, J. Costantino, C. Polychronakos, S.A. Blauer, H. Guyda, C. Redmond, B. Fisher, R. Margolese, Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst. 82(21), 1693–1697 (1990)PubMedCrossRef

22.

S.I. Helle, J.M. Holly, M. Tally, K. Hall, J. Vander Stappen, P.E. Lonning, Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int. J. Cancer 69(4), 335–339 (1996). doi:10.1002/(SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.0.CO;2-4PubMedCrossRef

23.

A. Decensi, B. Bonanni, A. Guerrieri-Gonzaga, S. Gandini, C. Robertson, H. Johansson, R. Travaglini, M.T. Sandri, A. Tessadrelli, G. Farante, F. Salinaro, D. Bettega, A. Barreca, P. Boyle, A. Costa, U. Veronesi, Biologic activity of tamoxifen at low doses in healthy women. J. Natl. Cancer Inst. 90(19), 1461–1467 (1998)PubMedCrossRef

24.

M. Mandala, C. Moro, G. Ferretti, M.G. Calabro, F. Nole, A. Rocca, E. Munzone, A. Castro, G. Curigliano, Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Anticancer Res. 21(1B), 585–588 (2001)PubMed

25.

V. Birzniece, A. Sata, S. Sutanto, K.K. Ho, Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. J. Clin. Endocrinol. Metab. 95(12), 5443–5448 (2010). doi:10.1210/jc.2010-1477 PubMedCrossRef

26.

V. Birzniece, K.K. Ho, Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes. Eur. J. Endocrinol. 173(4), 479–487 (2015). doi:10.1530/EJE-15-0426 PubMedCrossRef

27.

V. Birzniece, S. Sutanto, K.K. Ho, Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J. Clin. Endocrinol. Metab. 97(4), E521–527 (2012). doi:10.1210/jc.2011-3347 PubMedCrossRef

28.

D.B. Muchmore, Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5(5), 388–392 (2000)PubMedCrossRef

29.

A.M. Oleksik, T. Duong, N. Pliester, G. Asma, C. Popp-Snijders, P. Lips, Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J. Clin. Endocrinol. Metab. 86(6), 2763–2768 (2001). doi:10.1210/jcem.86.6.7549 PubMedCrossRef

30.

E.J. Duschek, G.W. de Valk-de Roo, L.J. Gooren, C. Netelenbos, Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study. Fertil. Steril. 82(2), 384–390 (2004). doi:10.1016/j.fertnstert.2004.01.033 PubMedCrossRef

31.

A. Cakmak, C. Posaci, E. Dogan, S. Caliskan, S. Guclu, S. Altunyurt, Raloxifene increases serum leptin levels in postmenopausal women: a prospective study. Am. J. Obstet. Gynecol. 193(2), 347–351 (2005). doi:10.1016/j.ajog.2005.01.023 PubMedCrossRef

32.

A. Lasco, A. Gaudio, E. Morini, N. Morabito, C. Nicita-Mauro, A. Catalano, G. Denuzzo, C. Sansotta, A. Xourafa, I. Macri, N. Frisina, Effect of long-term treatment with raloxifene on mammary density in postmenopausal women. Menopause 13(5), 787–792 (2006). doi:10.1097/01.gme.0000233493.20712.ad PubMedCrossRef

33.

R. Torrisi, L. Baglietto, H. Johansson, G. Veronesi, B. Bonanni, A. Guerrieri-Gonzaga, B. Ballardini, A. Decensi, Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br. J. Cancer 85(12), 1838–1841 (2001). doi:10.1054/bjoc.2001.2191 PubMedPubMedCentralCrossRef

34.

B.B. da Silva, D.S. Moita, C.G. Pires, E.C. Sousa-Junior, A.R. dos Santos, P.V. Lopes-Costa, Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene. Int. Semin. Surg. Oncol. 4, 18 (2007). doi:10.1186/1477-7800-4-18 PubMedPubMedCentralCrossRef

35.

V. Birzniece, U. Meinhardt, J. Gibney, G. Johannsson, R.C. Baxter, M.J. Seibel, K.K. Ho, Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women. J. Clin. Endocrinol. Metab. 95(5), 2099–2106 (2010). doi:10.1210/jc.2009-2743 PubMedCrossRef

36.

E.J. Duschek, L.J. Gooren, C. Netelenbos, Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas 51(3), 286–293 (2005). doi:10.1016/j.maturitas.2004.08.011 PubMedCrossRef

37.

J. Eng-Wong, S.D. Hursting, D. Venzon, S.N. Perkins, J.A. Zujewski, Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol. Biomarkers Prev. 12(12), 1468–1473 (2003)PubMed

38.

V. Birzniece, N.E. Magnusson, K.K. Ho, J. Frystyk, Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women. Eur. J. Endocrinol. 170(3), 375–383 (2014). doi:10.1530/EJE-13-0835 PubMedCrossRef

39.

Practice Committee of the American Society for Reproductive, M., Use of clomiphene citrate in infertile women: a committee opinion. Fertil. Steril. 100(2), 341–348 (2013). doi:10.1016/j.fertnstert.2013.05.033 CrossRef

40.

L.W. Roth, A.R. Ryan, R.B. Meacham, Clomiphene citrate in the management of male infertility. Semin. Reprod. Med 31(4), 245–250 (2013). doi:10.1055/s-0033-1345271 PubMedCrossRef

41.

T.L. Butzow, L.M. Kettel, S.S. Yen, Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome. Fertil. Steril. 63(6), 1200–1203 (1995)PubMedCrossRef

42.

V. de Leo, A. la Marca, G. Morgante, L. Ciotta, L. Mencaglia, A. Cianci, F. Petraglia, Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome. Hum. Reprod. 15(11), 2302–2305 (2000)PubMedCrossRef

43.

T.M. Fiad, T.P. Smith, S.K. Cunningham, T.J. McKenna, Decline in insulin-like growth factor I levels after clomiphene citrate does not correct hyperandrogenemia in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83(7), 2394–2398 (1998). doi:10.1210/jcem.83.7.4921 PubMedCrossRef

44.

A.A. Rouzi, M.S. Ardawi, A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil. Steril. 85(2), 428–435 (2006). doi:10.1016/j.fertnstert.2005.07.1312 PubMedCrossRef

45.

R.S. Morris, V.C. Karande, A. Dudkiewicz, J.L. Morris, N. Gleicher, Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. Fertil. Steril. 71(3), 452–456 (1999)PubMedCrossRef

46.

H. Huynh, M. Pollak, Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem. Biophys. Res. Commun. 203(1), 253–259 (1994). doi:10.1006/bbrc.1994.2175 PubMedCrossRef

47.

L. Canobbio, D. Cannata, L. Miglietta, F. Boccardo, Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res. 15(6B), 2687–2690 (1995)PubMed

48.

J.N. Ingle, V.J. Suman, C.G. Kardinal, J.E. Krook, J.A. Mailliard, M.H. Veeder, C.L. Loprinzi, R.J. Dalton, L.C. Hartmann, C.A. Conover, M.N. Pollak, A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85(6), 1284–1292 (1999)PubMedCrossRef

49.

M.N. Pollak, H.T. Huynh, S.P. Lefebvre, Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res. Treat. 22(1), 91–100 (1992)PubMedCrossRef

50.

H.M. Domene, G. Marin, J. Sztein, Y.M. Yu, J. Baron, F.G. Cassorla, Estradiol inhibits growth hormone receptor gene expression in rabbit liver. Mol. Cell Endocrinol. 103(1-2), 81–87 (1994). doi:0303-7207(94)90072-8 [pii]PubMedCrossRef

51.

K.K. Ho, E. Valiontis, M.J. Waters, I.A. Rajkovic, Regulation of growth hormone binding protein in man: comparison of gel chromatography and immunoprecipitation methods. J. Clin. Endocrinol. Metab. 76(2), 302–308 (1993). doi:10.1210/jcem.76.2.8432772 PubMed

52.

H.T. Huynh, E. Tetenes, L. Wallace, M. Pollak, In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 53(8), 1727–1730 (1993)PubMed

53.

K.C. Leung, G. Johannsson, G.M. Leong, K.K. Ho, Estrogen regulation of growth hormone action. Endocr. Rev. 25(5), 693–721 (2004). doi:10.1210/er.2003-0035 PubMedCrossRef

54.

G.M. Leong, S. Moverare, J. Brce, N. Doyle, K. Sjogren, K. Dahlman-Wright, J.A. Gustafsson, K.K. Ho, C. Ohlsson, K.C. Leung, Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology 145(12), 5525–5531 (2004). doi:10.1210/en.2004-0061 PubMedCrossRef

55.

K.C. Leung, N. Doyle, M. Ballesteros, K. Sjogren, C.K. Watts, T.H. Low, G.M. Leong, R.J. Ross, K.K. Ho, Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc. Natl. Acad. Sci. U S A 100(3), 1016–1021 (2003). doi:10.1073/pnas.0337600100 PubMedPubMedCentralCrossRef

56.

L. Fernandez, A. Flores-Morales, O. Lahuna, D. Sliva, G. Norstedt, L.A. Haldosen, A. Mode, J.A. Gustafsson, Desensitization of the growth hormone-induced Janus kinase 2 (Jak 2)/signal transducer and activator of transcription 5 (Stat5)-signaling pathway requires protein synthesis and phospholipase C. Endocrinology 139(4), 1815–1824 (1998). doi:10.1210/endo.139.4.5931 PubMed

57.

B. Mozzanega, G.L. Babbo, L. Salmaso, R. De Toni, A. Schiavo, R. Mioni, S.V. de Kreutzenberg, Oral 17beta-estradiol and sequential progesterone in menopause: effects on insulin-like growth factors and their binding proteins. Gynecol. Endocrinol. 23(1), 50–57 (2007)PubMedCrossRef

58.

E. Wiedemann, E. Schwartz, Suppression of growth hormone-dependent human serum sulfation factor by estrogen. J. Clin. Endocrinol. Metab. 34(1), 51–58 (1972)PubMedCrossRef

59.

D.R. Clemmons, L.E. Underwood, E.C. Ridgway, B. Kliman, R.N. Kjellberg, J.J. Van Wyk, Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am. J. Med. 69(4), 571–575 (1980). doi:0002-9343(80)90470-2 [pii]PubMedCrossRef

60.

S. Almqvist, D. Ikkos, R. Luft, Studies on sulfation factor (SF) activity of human serum. The effects of oestrogen and x-ray therapy on serum SF activity in acromegaly. Acta Endocrinol. (Copenh) 37, 138–147 (1961)

61.

S. Vallette, O. Serri, Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13(4), 311–314 (2010). doi:10.1007/s11102-010-0236-5 PubMedCrossRef

62.

I. Shimon, A. Barkan, Estrogen treatment for acromegaly. Pituitary 15(4), 601–607 (2012). doi:10.1007/s11102-012-0426-4 PubMedCrossRef

63.

R. Cozzi, M. Barausse, S. Lodrini, G. Lasio, R. Attanasio, Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J. Endocrinol. Invest. 26(4), 347–352 (2003). doi:10.1007/BF03345183 PubMedCrossRef

64.

R. Cozzi, R. Attanasio, G. Oppizzi, P. Orlandi, A. Giustina, S. Lodrini, N. Da Re, D. Dallabonzana: Effects of tamoxifen on GH and IGF-I levels in acromegaly. J. Endocrinol. Invest. 20(8), 445–451 (1997)PubMedCrossRef

65.

J.C. Maiza, S. Castillo-Ros, M. Matta, A. Bennet, P. Caron, Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide. Pituitary 15(Suppl 1), S23–S27 (2012). doi:10.1007/s11102-010-0287-7 PubMedCrossRef

66.

I. Balili, A. Barkan, Tamoxifen as a therapeutic agent in acromegaly. Pituitary 17(6), 500–504 (2014). doi:10.1007/s11102-013-0534-9 PubMedCrossRef

67.

R. Attanasio, M. Barausse, R. Cozzi, Raloxifene lowers IGF-I levels in acromegalic women. Eur. J. Endocrinol. 148(4), 443–448 (2003)PubMedCrossRef

68.

E.V. Dimaraki, K.V. Symons, A.L. Barkan, Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur. J. Endocrinol. 150(4), 481–487 (2004)PubMedCrossRef

69.

F.H. Duarte, R.S. Jallad, M.D. Bronstein, Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. J. Clin. Endocrinol. Metab. 100(5), 1863–1869 (2015). doi:10.1210/jc.2014-3913 PubMedCrossRef

70.

J.C. Stone, J. Clark, R. Cuneo, A.W. Russell, S.A. Doi, Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies. Pituitary 17(3), 284–295 (2014). doi:10.1007/s11102-013-0504-2 PubMedCrossRef

Title: Estrogens and selective estrogen receptor modulators in acromegaly
Authors: Felipe H. Duarte
Raquel S. Jallad
Marcello D. Bronstein
Publication date: 01-11-2016
Publisher: Springer US
Published in: Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-016-1118-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

A hypothetical model to solve the controversy over the involvement of UCP2 in palmitate-induced β-cell dysfunction

Allocation of parathyroid adenoma and suspicious thyroid nodule by real-time 99mTc-MIBI SPECT/US fusion imaging

Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients

Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouse

High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures

Evaluation of patient-reported outcomes data in structured diabetes education intervention: 2-year follow-up data of patient empowerment programme

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials